强生第二季度销售额237.4亿美元，预估228.4亿美元。第二季度调整后每股收益2.77美元。第二季度STELARA收入16.5亿美元，预估17.7亿美元。强生预计全年销售额932亿美元至936亿美元，此前预计910亿美元至918亿美元。强生预计全年调整后每股收益10.80美元至10.90美元，此前预计10.50美元至10.70美元。强生美股盘前涨超1%。

Group 1 - The core viewpoint of the article highlights Johnson & Johnson's strong second-quarter performance, with sales exceeding expectations and an increase in full-year guidance [1] - The company reported second-quarter sales of $23.74 billion, surpassing the forecast of $22.84 billion [1] - Adjusted earnings per share for the second quarter were $2.77, indicating solid profitability [1] Group 2 - STELARA, a key product, generated $1.65 billion in revenue for the second quarter, slightly below the expected $1.77 billion [1] - Johnson & Johnson raised its full-year sales forecast to between $93.2 billion and $93.6 billion, up from the previous estimate of $91 billion to $91.8 billion [1] - The company also increased its full-year adjusted earnings per share guidance to between $10.80 and $10.90, compared to the prior range of $10.50 to $10.70 [1] Group 3 - Following the positive earnings report, Johnson & Johnson's stock rose over 1% in pre-market trading [1]